Retrospective view over the decades of post human genome research, a number of major pharmaceutical biotechnologies have been maturing to produce new medicines for treatment of different diseases, however, more or less hampered with critical bottlenecks, which resulted in the low efficiency in turnover and high cost in time and risk, on the way in their research and development. The NHP experimental models appear to be a powerful tool with the output of high translatability to human for solving these issues in nonclinical and clinical advancement.
Sie sind vermutlich noch nicht im Forum angemeldet - Klicken Sie hier um sich kostenlos anzumelden